（原标题：【券商聚焦】东北证券首予石药集团(01093.HK)“买入”评级 指与阿斯利康合作升级加速全球化布局）金吾财讯|东北证券发布研报指，石药集团(01093.HK)与阿斯利康签订战略研发合作与授权协议，围绕长效多肽与AI制药技术平台展开合作，潜在交易总金额达185亿美元（含预付款及里程碑付款）。该合作标志着双方全球化合作持续升级，有望加速公司长效多肽药物的全球布局。 研报指出，公司核心技术...
Source Link（原标题：【券商聚焦】东北证券首予石药集团(01093.HK)“买入”评级 指与阿斯利康合作升级加速全球化布局）金吾财讯|东北证券发布研报指，石药集团(01093.HK)与阿斯利康签订战略研发合作与授权协议，围绕长效多肽与AI制药技术平台展开合作，潜在交易总金额达185亿美元（含预付款及里程碑付款）。该合作标志着双方全球化合作持续升级，有望加速公司长效多肽药物的全球布局。 研报指出，公司核心技术...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.